Supplementary Figure 5 from MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide Article Swipe
Oihane Erice
,
Michael P. Smith
,
Rachel White
,
Ibai Goicoechea
,
Jorge Barriuso
,
Chris Jones
,
Geoffrey P. Margison
,
Juan Carlos Acosta
,
Claudia Wellbrock
,
Imanol Arozarena
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1158/1535-7163.22502749
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1158/1535-7163.22502749
Supplementary Figure 5. A, Colony formation assay on WM98.1 clones expressing an empty vector (vector) or MGMT (MGMT) treated with TMZ with or without veliparib (ABT). B, GI50s of the same WM98.1 clones treated with MMS with our without olaparib veliparib. PF50 values are also shown. D, GI50s of the 10 melanoma cell lines treated with MMS with our without olaparib veliparib. PF50 values are also shown. E, MGMT in vitro activity assays. Recombinant MGMT was incubated with increasing concentrations of olaparib, veliparib or lomeguatrib
Related Topics
Concepts
Veliparib
Olaparib
Temozolomide
PARP inhibitor
Cancer research
Poly ADP ribose polymerase
Medicine
Molecular biology
Biology
Oncology
Glioblastoma
Genetics
DNA
Polymerase
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.1158/1535-7163.22502749
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4362495302
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4362495302Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1158/1535-7163.22502749Digital Object Identifier
- Title
-
Supplementary Figure 5 from MGMT Expression Predicts PARP-Mediated Resistance to TemozolomideWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-04-03Full publication date if available
- Authors
-
Oihane Erice, Michael P. Smith, Rachel White, Ibai Goicoechea, Jorge Barriuso, Chris Jones, Geoffrey P. Margison, Juan Carlos Acosta, Claudia Wellbrock, Imanol ArozarenaList of authors in order
- Landing page
-
https://doi.org/10.1158/1535-7163.22502749Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1158/1535-7163.22502749Direct OA link when available
- Concepts
-
Veliparib, Olaparib, Temozolomide, PARP inhibitor, Cancer research, Poly ADP ribose polymerase, Medicine, Molecular biology, Biology, Oncology, Glioblastoma, Genetics, DNA, PolymeraseTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4362495302 |
|---|---|
| doi | https://doi.org/10.1158/1535-7163.22502749 |
| ids.doi | https://doi.org/10.1158/1535-7163.22502749 |
| ids.openalex | https://openalex.org/W4362495302 |
| fwci | 0.0 |
| type | preprint |
| title | Supplementary Figure 5 from MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T11914 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2730 |
| topics[0].subfield.display_name | Oncology |
| topics[0].display_name | PARP inhibition in cancer therapy |
| topics[1].id | https://openalex.org/T12255 |
| topics[1].field.id | https://openalex.org/fields/24 |
| topics[1].field.display_name | Immunology and Microbiology |
| topics[1].score | 0.9606000185012817 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2403 |
| topics[1].subfield.display_name | Immunology |
| topics[1].display_name | Biosimilars and Bioanalytical Methods |
| topics[2].id | https://openalex.org/T11491 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9580000042915344 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | CAR-T cell therapy research |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2781312401 |
| concepts[0].level | 5 |
| concepts[0].score | 0.9941920042037964 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q7919041 |
| concepts[0].display_name | Veliparib |
| concepts[1].id | https://openalex.org/C2779962180 |
| concepts[1].level | 5 |
| concepts[1].score | 0.9757364988327026 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q7083106 |
| concepts[1].display_name | Olaparib |
| concepts[2].id | https://openalex.org/C2777389519 |
| concepts[2].level | 3 |
| concepts[2].score | 0.8217848539352417 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q425088 |
| concepts[2].display_name | Temozolomide |
| concepts[3].id | https://openalex.org/C2779138821 |
| concepts[3].level | 5 |
| concepts[3].score | 0.7221936583518982 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q7118227 |
| concepts[3].display_name | PARP inhibitor |
| concepts[4].id | https://openalex.org/C502942594 |
| concepts[4].level | 1 |
| concepts[4].score | 0.52760910987854 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[4].display_name | Cancer research |
| concepts[5].id | https://openalex.org/C182979987 |
| concepts[5].level | 4 |
| concepts[5].score | 0.47017139196395874 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q3907241 |
| concepts[5].display_name | Poly ADP ribose polymerase |
| concepts[6].id | https://openalex.org/C71924100 |
| concepts[6].level | 0 |
| concepts[6].score | 0.4108654856681824 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[6].display_name | Medicine |
| concepts[7].id | https://openalex.org/C153911025 |
| concepts[7].level | 1 |
| concepts[7].score | 0.35956132411956787 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q7202 |
| concepts[7].display_name | Molecular biology |
| concepts[8].id | https://openalex.org/C86803240 |
| concepts[8].level | 0 |
| concepts[8].score | 0.3433002233505249 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[8].display_name | Biology |
| concepts[9].id | https://openalex.org/C143998085 |
| concepts[9].level | 1 |
| concepts[9].score | 0.32418525218963623 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[9].display_name | Oncology |
| concepts[10].id | https://openalex.org/C2776194525 |
| concepts[10].level | 2 |
| concepts[10].score | 0.2004014551639557 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q282142 |
| concepts[10].display_name | Glioblastoma |
| concepts[11].id | https://openalex.org/C54355233 |
| concepts[11].level | 1 |
| concepts[11].score | 0.14174729585647583 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q7162 |
| concepts[11].display_name | Genetics |
| concepts[12].id | https://openalex.org/C552990157 |
| concepts[12].level | 2 |
| concepts[12].score | 0.12350296974182129 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q7430 |
| concepts[12].display_name | DNA |
| concepts[13].id | https://openalex.org/C82381507 |
| concepts[13].level | 3 |
| concepts[13].score | 0.1142708957195282 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q416878 |
| concepts[13].display_name | Polymerase |
| keywords[0].id | https://openalex.org/keywords/veliparib |
| keywords[0].score | 0.9941920042037964 |
| keywords[0].display_name | Veliparib |
| keywords[1].id | https://openalex.org/keywords/olaparib |
| keywords[1].score | 0.9757364988327026 |
| keywords[1].display_name | Olaparib |
| keywords[2].id | https://openalex.org/keywords/temozolomide |
| keywords[2].score | 0.8217848539352417 |
| keywords[2].display_name | Temozolomide |
| keywords[3].id | https://openalex.org/keywords/parp-inhibitor |
| keywords[3].score | 0.7221936583518982 |
| keywords[3].display_name | PARP inhibitor |
| keywords[4].id | https://openalex.org/keywords/cancer-research |
| keywords[4].score | 0.52760910987854 |
| keywords[4].display_name | Cancer research |
| keywords[5].id | https://openalex.org/keywords/poly-adp-ribose-polymerase |
| keywords[5].score | 0.47017139196395874 |
| keywords[5].display_name | Poly ADP ribose polymerase |
| keywords[6].id | https://openalex.org/keywords/medicine |
| keywords[6].score | 0.4108654856681824 |
| keywords[6].display_name | Medicine |
| keywords[7].id | https://openalex.org/keywords/molecular-biology |
| keywords[7].score | 0.35956132411956787 |
| keywords[7].display_name | Molecular biology |
| keywords[8].id | https://openalex.org/keywords/biology |
| keywords[8].score | 0.3433002233505249 |
| keywords[8].display_name | Biology |
| keywords[9].id | https://openalex.org/keywords/oncology |
| keywords[9].score | 0.32418525218963623 |
| keywords[9].display_name | Oncology |
| keywords[10].id | https://openalex.org/keywords/glioblastoma |
| keywords[10].score | 0.2004014551639557 |
| keywords[10].display_name | Glioblastoma |
| keywords[11].id | https://openalex.org/keywords/genetics |
| keywords[11].score | 0.14174729585647583 |
| keywords[11].display_name | Genetics |
| keywords[12].id | https://openalex.org/keywords/dna |
| keywords[12].score | 0.12350296974182129 |
| keywords[12].display_name | DNA |
| keywords[13].id | https://openalex.org/keywords/polymerase |
| keywords[13].score | 0.1142708957195282 |
| keywords[13].display_name | Polymerase |
| language | en |
| locations[0].id | doi:10.1158/1535-7163.22502749 |
| locations[0].is_oa | True |
| locations[0].source | |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.1158/1535-7163.22502749 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5081538932 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-9894-1356 |
| authorships[0].author.display_name | Oihane Erice |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Oihane Erice |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5102429776 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Michael P. Smith |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Michael P. Smith |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5083905242 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-4013-2732 |
| authorships[2].author.display_name | Rachel White |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Rachel White |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5055467929 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-5329-2225 |
| authorships[3].author.display_name | Ibai Goicoechea |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Ibai Goicoechea |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5060729173 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-5641-9105 |
| authorships[4].author.display_name | Jorge Barriuso |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Jorge Barriuso |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5031621086 |
| authorships[5].author.orcid | https://orcid.org/0000-0001-8118-2296 |
| authorships[5].author.display_name | Chris Jones |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Chris Jones |
| authorships[5].is_corresponding | False |
| authorships[6].author.id | https://openalex.org/A5077801086 |
| authorships[6].author.orcid | https://orcid.org/0009-0001-5471-918X |
| authorships[6].author.display_name | Geoffrey P. Margison |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Geoffrey P. Margison |
| authorships[6].is_corresponding | False |
| authorships[7].author.id | https://openalex.org/A5091070429 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-7989-7329 |
| authorships[7].author.display_name | Juan Carlos Acosta |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Juan C. Acosta |
| authorships[7].is_corresponding | False |
| authorships[8].author.id | https://openalex.org/A5082118845 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-3825-6381 |
| authorships[8].author.display_name | Claudia Wellbrock |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Claudia Wellbrock |
| authorships[8].is_corresponding | False |
| authorships[9].author.id | https://openalex.org/A5007234389 |
| authorships[9].author.orcid | https://orcid.org/0000-0001-6349-2442 |
| authorships[9].author.display_name | Imanol Arozarena |
| authorships[9].author_position | last |
| authorships[9].raw_author_name | Imanol Arozarena |
| authorships[9].is_corresponding | False |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1158/1535-7163.22502749 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Supplementary Figure 5 from MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11914 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2730 |
| primary_topic.subfield.display_name | Oncology |
| primary_topic.display_name | PARP inhibition in cancer therapy |
| related_works | https://openalex.org/W2808701886, https://openalex.org/W2139802796, https://openalex.org/W4362495302, https://openalex.org/W2003243316, https://openalex.org/W4362484440, https://openalex.org/W2366612842, https://openalex.org/W4361884197, https://openalex.org/W2172423041, https://openalex.org/W4362494957, https://openalex.org/W4362494665 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1158/1535-7163.22502749 |
| best_oa_location.is_oa | True |
| best_oa_location.source | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.1158/1535-7163.22502749 |
| primary_location.id | doi:10.1158/1535-7163.22502749 |
| primary_location.is_oa | True |
| primary_location.source | |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.1158/1535-7163.22502749 |
| publication_date | 2023-04-03 |
| publication_year | 2023 |
| referenced_works_count | 0 |
| abstract_inverted_index.10 | 50 |
| abstract_inverted_index.5. | 2 |
| abstract_inverted_index.A, | 3 |
| abstract_inverted_index.B, | 26 |
| abstract_inverted_index.D, | 46 |
| abstract_inverted_index.E, | 67 |
| abstract_inverted_index.an | 11 |
| abstract_inverted_index.in | 69 |
| abstract_inverted_index.of | 28, 48, 80 |
| abstract_inverted_index.on | 7 |
| abstract_inverted_index.or | 15, 22, 83 |
| abstract_inverted_index.MMS | 35, 56 |
| abstract_inverted_index.TMZ | 20 |
| abstract_inverted_index.are | 43, 64 |
| abstract_inverted_index.our | 37, 58 |
| abstract_inverted_index.the | 29, 49 |
| abstract_inverted_index.was | 75 |
| abstract_inverted_index.MGMT | 16, 68, 74 |
| abstract_inverted_index.PF50 | 41, 62 |
| abstract_inverted_index.also | 44, 65 |
| abstract_inverted_index.cell | 52 |
| abstract_inverted_index.same | 30 |
| abstract_inverted_index.with | 19, 21, 34, 36, 55, 57, 77 |
| abstract_inverted_index.GI50s | 27, 47 |
| abstract_inverted_index.assay | 6 |
| abstract_inverted_index.empty | 12 |
| abstract_inverted_index.lines | 53 |
| abstract_inverted_index.vitro | 70 |
| abstract_inverted_index.(ABT). | 25 |
| abstract_inverted_index.(MGMT) | 17 |
| abstract_inverted_index.Colony | 4 |
| abstract_inverted_index.Figure | 1 |
| abstract_inverted_index.WM98.1 | 8, 31 |
| abstract_inverted_index.clones | 9, 32 |
| abstract_inverted_index.shown. | 45, 66 |
| abstract_inverted_index.values | 42, 63 |
| abstract_inverted_index.vector | 13 |
| abstract_inverted_index.assays. | 72 |
| abstract_inverted_index.treated | 18, 33, 54 |
| abstract_inverted_index.without | 23, 38, 59 |
| abstract_inverted_index.(vector) | 14 |
| abstract_inverted_index.activity | 71 |
| abstract_inverted_index.melanoma | 51 |
| abstract_inverted_index.olaparib | 39, 60 |
| abstract_inverted_index.formation | 5 |
| abstract_inverted_index.incubated | 76 |
| abstract_inverted_index.olaparib, | 81 |
| abstract_inverted_index.veliparib | 24, 82 |
| abstract_inverted_index.expressing | 10 |
| abstract_inverted_index.increasing | 78 |
| abstract_inverted_index.veliparib. | 40, 61 |
| abstract_inverted_index.Recombinant | 73 |
| abstract_inverted_index.concentrations | 79 |
| abstract_inverted_index.lomeguatrib</p> | 84 |
| abstract_inverted_index.<p>Supplementary | 0 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 10 |
| citation_normalized_percentile.value | 0.25634657 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |